Clinical trials: Irinotecan
Metastatic Colorectal Cancer
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment
Investigators propose to study the combination of m FOLFIRI plus Aflibercept in a Phase II trial of patients with metastatic colorectal cancer.
- Trial name
- MINOAS (NCT02624726)
- Testing
- 5 Fluorouracil, Leucovorin, Irinotecan
- Where
- 10 sites in Greece
- Volunteers
- 31 people
- Sponsor
- Hellenic Oncology Research Group
Colorectal Cancer
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
Bevacizumab has recently been shown to improve survival when combined with chemotherapy in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00483834
- Testing
- Bevacizumab, Irinotecan, Capecitabine
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28
This trial aims to evaluate the efficacy, safety of high-dose FOLFIRI regimen in advanced colorectal cancer patients with wild-type UGT1A1*6 and *28.
- Trial name
- NCT03329183
- Testing
- Irinotecan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Changzheng Hospital
Ewing's Tumor Metastatic
Anlotinib and Irinotecan for Ewing Sarcoma
The investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma.
- Trial name
- NCT03416517
- Testing
- Anlotinib, Irinotecan
- Where
- 5 sites in China
- Volunteers
- 47 people
- Sponsor
- Peking University People's Hospital
Lung Cancer
Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer
Evaluate the efficacy and toxicity of the weekly combination chemotherapy of Paclitaxel, Carboplatin and Irinotecan in Stage IIIb and IV NSCLC with malignant pleural effusion
- Trial name
- NCT00465907
- Testing
- Paclitaxel, Carboplatin and Irinotecan
- Where
- Singapore
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Colorectal Carcinoma, Thrombopenia
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with…
- Trial name
- NCT03823079
- Testing
- rhTPO, irinotecan, Raltitrexed
- Volunteers
- 50 people
- Sponsor
- Fudan University
Stage IV Colorectal Cancer, Gastric Cancer
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
The purpose of this study is to investigate the association between UGT1A1 polymorphisms and neutropenia and diarrhea in Korean patients with advanced colorectal or gastric cancer treated with FOLFIRI regimen.
- Trial name
- NCT01271582
- Testing
- Irinotecan, 5FU, leucovorin
- Where
- 5 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Asan Medical Center
Locally Advanced Rectal Cancer
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
The study evaluates the addition of Amifostine to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer.
- Trial name
- NCT03702985
- Testing
- Radiation, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Colorectal Neoplasms
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
This open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (PFS) in participants with previously untreated metastatic colorectal cancer.
- Trial name
- ASCENT (NCT01588990)
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 17 sites in Australia
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of…
- Trial name
- NCT01925274
- Testing
- PF-05212384, irinotecan, Cetuximab
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 19 people
- Sponsor
- Pfizer
Colorectal Neoplasms, Neoplasm Metastasis
A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
The primary purpose of this study is to determine the non-inferiority of overall survival XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as Second-line therapy in Patient with Metastatic…
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms
- Trial name
- AXEPT (NCT01996306)
- Testing
- Bevacizumab, CPT-11 (Irinotecan), 5-FU Bolus
- Where
- Japan
- Volunteers
- 650 people
- Sponsor
- Epidemiological and Clinical Research Information Network
Metastatic Colorectal Cancer
RSHF in Colorectal Cancer
The purpose of this study is to study stereotactic radiotherapy with a dose of 40 Gy in 4 fractions over 2 weeks with concomitant 40 mg/m2 of irinotecan (1st and 3rd irradiation session).
- Trial name
- RS CAMPTO (NCT01220063)
- Testing
- Radiation, Irinotecan
- Where
- 6 sites in France
- Volunteers
- 48 people
- Sponsor
- Institut Cancerologie de l'Ouest
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
This phase I trial studies the side effects and best dose of alisertib when given together with irinotecan hydrochloride in treating patients with advanced solid tumors or colorectal cancer.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01923337
- Testing
- irinotecan hydrochloride, alisertib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Davis
Colorectal Cancer Metastatic, Chemotherapy Effect
Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
XELOX as first-line treatment regimen has limited efficacy against patients with metastatic colorectal cancer (mCRC). Peritoneal metastasis is one of the most lethal factor for mCRC.
- Conditions
- Colorectal Cancer Metastatic, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- NCT03792269
- Testing
- Irinotecan, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
KRAS Mutant Metastatic Colorectal Cancer
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
This is a Phase 1 dose-escalation study with three dose levels to determine the maximum tolerated dose of REOLYSIN® combined with FOLFIRI and bevacizumab.
- Trial name
- NCT01274624
- Testing
- REOLYSIN®, Irinotecan, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Oncolytics Biotech
Head and Neck Cancer
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100828
- Testing
- irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
This randomized phase III trial is comparing the effectiveness of three adjuvant combination chemotherapy regimens in treating patients who are receiving radiation therapy and fluorouracil either before or after surgery for stage…
- Conditions
- Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7
- Trial name
- NCT00068692
- Testing
- Radiotherapy, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or…
- Trial name
- NCT00003245
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St.
- Trial name
- NCT01576692
- Testing
- Humanized anti-GD2 antibody, Chemotherapy, Cytokines
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Malignant Gliomas
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide combined with Camptosar (irinotecan) as well as to see if this drug combination can help control malignant gliomas.
- Trial name
- NCT00671801
- Testing
- Irinotecan, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center